Examining autistic traits and sensory profiles in children with Prader-Willi Syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on children diagnosed with Prader-Willi Syndrome (PWS) to explore their autistic symptomatology and sensory profiles. It aims to identify the unique characteristics of autism in PWS, which is often overlooked in standard care. The study will involve psychological and sensory assessments, and it will also consider the effects of early oxytocin treatment on these traits. By aligning with recommendations for early intervention, the study seeks to improve understanding and management of PWS-related challenges.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Child with genetically confirmed PWS and identification of genetic subtype;
* Child aged between 3 and 16 years;
* Hospitalisation or multidisciplinary consultation planned for the child's routine follow-up at one of the investigating centres;
* No parental/legal guardian objection.

Exclusion Criteria:

* Change in psychotropic treatment (start, change in dose or discontinuation) in the past 3 months;
* Inability to provide clear information to parents/legal guardian;
* Not covered by social security.

Where it's running

• Children Hospital
  Toulouse, France Recruiting

Study contacts

• Principal investigator: Sophie Cabal — University Hospital of Toulouse
• Study coordinator: Nadege ALGANS
• Email: algans.n@chu-toulouse.fr
• Phone: 0561777204

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Group therapy to help teens with Prader-Willi regulate emotions

  Teens with Prader-Willi Syndrome and their families will try a group therapy program to help calm emotions and reduce irritability and anxiety.

  Recruiting Children's Mercy Hospital Kansas City · Kansas City, Missouri · NCT07607730

• CSTI-500 in Prader-Willi Syndrome: a dose-escalation study for safety and efficacy

  This study tests CSTI-500 in people aged 13–50 with Prader-Willi syndrome to see if it is safe and helps with symptoms, using increasing doses guided by blood levels.

  Recruiting Phase 2 ConSynance Therapeutics · Nashville, Tennessee · NCT07348601

• Using Tirzepatide to treat obesity in young adults with Prader-Willi Syndrome and hypothalamic obesity

  This study is testing if a weight loss medication called Tirzepatide can help young adults with Prader-Willi Syndrome and hypothalamic obesity lose weight and improve their health.

  Recruiting at 3 sites Phase 4 Seattle Children's Hospital · Saint Paul, Minnesota and 2 other locations · NCT06901245

• Inclusive physical activity program for adults with intellectual disabilities

  This study is testing a new fitness program for adults with intellectual disabilities to see if it helps them be more active and feel better over 16 weeks.

  Recruiting University of North Carolina, Chapel Hill · Fayetteville, Arkansas and 1 other locations · NCT06740162

• Using vagus nerve stimulation to improve emotion and thinking in Prader-Willi Syndrome

  This study is testing whether a new treatment using vagus nerve stimulation can help improve emotions and thinking skills in adults with Prader-Willi Syndrome.

  Recruiting at 3 sites University of Bordeaux · Bordeaux and 3 other locations · NCT06720571

• Registry for Rare Diseases

  This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.

  Recruiting Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires · NCT06573723

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.